Loading...
XNASRSLS
Market cap3mUSD
Dec 24, Last price  
4.46USD
1D
4.69%
1Q
-21.48%
Jan 2017
-100.00%
IPO
-100.00%
Name

ReShape Lifesciences Inc

Chart & Performance

D1W1MN
XNAS:RSLS chart
P/E
—
P/S
0.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
51.92%
Rev. gr., 5y
70.25%
Revenues
9m
-22.79%
00000000312,00000292,000786,6601,287,154606,71015,089,00011,299,00013,600,00011,240,0008,678,000
Net income
-11m
L-75.36%
-3,448,752-11,215,191-17,690,477-28,575,348-37,874,028-31,929,000-17,347,000-25,997,322-23,460,000-25,781,000-26,129,000-25,499,000-23,360,844-33,817,972-81,151,575-74,207,000-21,630,000-61,933,000-46,214,000-11,387,000
CFO
-17m
L-22.56%
-10,278,090-16,228,123-23,368,510-33,668,613-24,657,223-13,664,607-19,935,434-22,479,369-18,425,729-19,383,663-22,606,040-20,655,793-24,588,208-27,490,170-14,200,000-8,550,000-15,375,000-21,902,000-16,960,000
Earnings
May 13, 2025

Profile

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
URL
https://www.reshapelifesciences.com/obalon/
IPO date
Oct 06, 2016
Employees
40
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,678
-22.79%
11,240
-17.35%
13,600
20.36%
Cost of revenue
23,317
38,318
41,349
Unusual Expense (Income)
NOPBT
(14,639)
(27,078)
(27,749)
NOPBT Margin
Operating Taxes
52
(380)
(106)
Tax Rate
NOPAT
(14,691)
(26,698)
(27,643)
Net income
(11,387)
-75.36%
(46,214)
-25.38%
(61,933)
186.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
17,574
639
2,813
BB yield
-1,181.57%
-0.39%
-0.27%
Debt
Debt current
222
171
279
Long-term debt
413
171
279
Deferred revenue
Other long-term liabilities
72
2,484
300
Net debt
(3,824)
(3,513)
(21,652)
Cash flow
Cash from operating activities
(16,960)
(21,902)
(15,375)
CAPEX
(43)
(131)
(352)
Cash from investing activities
(10)
(92)
1,855
Cash from financing activities
17,574
3,130
33,299
FCF
(16,475)
(25,459)
(31,099)
Balance
Cash
4,459
3,855
22,765
Long term investments
(555)
Excess cash
4,025
3,293
21,530
Stockholders' equity
(635,639)
(624,274)
(576,834)
Invested Capital
642,747
627,864
623,178
ROIC
ROCE
EV
Common stock shares outstanding
103
424
219
Price
14.48
-96.30%
390.92
-91.78%
4,756.00
-53.80%
Market cap
1,487
-99.10%
165,903
-84.04%
1,039,291
287.81%
EV
(2,337)
162,390
1,017,639
EBITDA
(14,485)
(24,925)
(25,778)
EV/EBITDA
0.16
Interest
113
832
Interest/NOPBT